Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 11/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 1.00 |
| ▸ | PPARD | Q03181 | 2/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24414338 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL13298743 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL21704479 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL29700194 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL13317693 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL21704478 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL24414320 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL21704576 | 0.90 | ADORA2A (0.81) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL13298745 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG | |
| SCHEMBL24414330 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADORA3PPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018371-B2 | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient | FM THERAPEUTICS CO., LTD. (KR) | 2015-04-28 | — | — | US | claimed |
| EP-2142549-B1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM THERAPEUTICS CO LTD (KR) | 2013-07-10 | — | — | EP | claimed |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FUTURE MEDICINE CO., LTD. (KR) | 2010-06-03 | — | — | US | claimed |
| US-20240366651-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ADENOSINE DERIVATIVE FOR PREVENTION AND TREATMENT OF RETINAL DISEASE OR OPTIC NERVE DISEASE | FUTURE MEDICINE CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20240325399-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHOLANGITIS OR LIVER DISEASE CAUSED BY CHOLANGITIS COMPRISING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO., LTD. (KR) | 2024-10-03 | — | — | US | disclosed |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2024-09-10 | — | — | US | disclosed |
| US-12076334-B2 | Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease | FUTURE MEDICINE CO., LTD. (KR) | 2024-09-03 | — | — | US | disclosed |
| EP-3603647-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO LTD (KR) | 2024-08-21 | — | — | EP | disclosed |
| EP-3725317-B1 | PHARMACEUTICAL COMPOSITION COMPRISING ADENOSINE DERIVATIVE FOR PREVENTION AND TREATMENT OF RETINAL DISEASE OR OPTIC NERVE DISEASE | FUTURE MEDICINE CO LTD (KR) | 2024-02-07 | — | — | EP | disclosed |
| EP-4234021-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOSINE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF DIABETIC NEPHROPATHY | Future Medicine Co., Ltd. (KR) | 2023-08-30 | — | — | EP | disclosed |
| EP-3650029-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOSINE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF DIABETIC NEPHROPATHY | FUTURE MEDICINE CO LTD (KR) | 2023-06-28 | — | — | EP | disclosed |
| CN-111432822-A | Pharmaceutical composition for preventing or treating retinal disease or optic nerve disease comprising adenosine derivative | 未来制药有限公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3650029-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DIABETIC NEPHROPATHY INCLUDING ADENOSINE DERIVATIVE | Future Medicine Co., Ltd. (KR) | 2020-05-13 | — | — | EP | disclosed |
| CN-110869030-A | Pharmaceutical composition for preventing and treating diabetic nephropathy comprising adenosine derivative | 未来制药有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20200046711-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | FUTURE MEDICINE CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| EP-3603647-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | Future Medicine Co., Ltd. (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3533452-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | Future Medicine Co., Ltd. (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-9018371-B2 | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient | FM THERAPEUTICS CO., LTD. (KR) | 2015-04-28 | — | — | US | disclosed |
| WO-2012125400-A1 | COMPOSITIONS AND METHODS USING ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY EYE DISEASES | ACORN BIOMEDICAL, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FUTURE MEDICINE CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366651-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ADENOSINE DERIVATIVE FOR PREVENTION AND TREATMENT OF RETINAL DISEASE OR OPTIC NERVE DISEASE | ADORA1, ADORA2B, PDE6C | ADORA2A 5/4885ADORA1 1/4885ADORA3 6/4885 |
| US-12076334-B2 | Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease | ADORA1, PDE6C, PDE6D | ADORA2A 6/4885ADORA1 1/4885ADORA3 5/4885 |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-20240325399-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHOLANGITIS OR LIVER DISEASE CAUSED BY CHOLANGITIS COMPRISING ADENOSINE DERIVATIVE | SLC10A1, ABCB11, SLC10A2 | ADORA2A 8/4885ADORA1 4/4885ADORA3 11/4885 |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA3 1/4885 |
| US-20200046711-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | SLC10A1, ADORA1, LIPC | ADORA2A 5/4885ADORA1 2/4885ADORA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.